MedPath
HSA Approval

ERYSOL FOR ORAL SUSPENSION 200 mg/5 ml

SIN00126P

ERYSOL FOR ORAL SUSPENSION 200 mg/5 ml

ERYSOL FOR ORAL SUSPENSION 200 mg/5 ml

March 18, 1988

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

GRANULE, FOR SUSPENSION

ORAL

Medical Information

J01FA01

erythromycin

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

ERYTHROMYCIN ETHYLSUCCINATE EQV ERYTHROMYCIN

200 mg/5 ml

Erythromycin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.